Rare-disease research at risk, says Europe’s pharma industry

Commission proposals on drug regulation would decrease innovation, companies reiterate

A proposal to overhaul EU pharmaceutical regulation “risks undermining two decades” of progress on treating rare diseases and could stymie innovation for them, the drug industry has warned.

The European Federation of Pharmaceutical Industries and Associations released a report on 22 September on the European Commission’s planned changes, including to the European Orphan Medicinal Product Regulation, which was introduced in 2000 to incentivise the development of medicines for rare diseases.

This article is only available to Research Professional News subscribers or Pivot-RP users.

If you are a Research Professional News subscriber you can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source